News & Media

202420232022202120202019201820172016201520142013
Press release 2019/12/18
Investigator-initiated phase II clinical study of remetinostat started in patients with squamous cell carcinoma

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled and is being dosed...

Read more
Press release 2019/12/16 Regulatory
Futility analysis performed of the phase II combination study with birinapant and Keytruda® in colorectal cancer patients

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces today that the independent safety committee (IDMC) for the phase II study...

Read more
Press release 2019/12/10
Medivir receives the International Diamond Prize for Excellence in Quality

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company has been awarded the International Diamond Prize for...

Read more
Press release 2019/11/27 Regulatory
MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2019

July – September Financial summary Net turnover amounted to SEK 1.7 (3.0) million. The loss before interest, tax, depreciation and amortization...

Read more
Press release 2019/11/18
Medivir reports last patient recruited to the phase Ia study of MIV-818 in liver cancer patients and initial dose determined for phase Ib

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) reports today that the ninth and final patient was recruited to the phase...

Read more
Press release 2019/10/30
Medivir presents MIV-818 data at AACR-NCI-EORTC in Boston

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that a poster entitled “MIV-818 stimulates an anti-tumor immune response in...

Read more
Press release 2019/10/10
US National Cancer Institute initiates phase I study of treatment of head and neck cancer patients with Medivir’s birinapant and radiation therapy

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled in a phase I...

Read more
Press release 2019/08/28 Regulatory
MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2019

April – JuneSignificant events during the quarter Selective effect signal on liver cancer tissue in phase Ia study with MIV-818. The...

Read more
Press release 2019/06/13 Regulatory
Selective effect signal on liver cancer tissue in phase Ia study with MIV-818

Stockholm, Sweden – Medivir AB (Nasdaq, Stockholm: MVIR) today announces the results of an analysis of data from the first six...

Read more
Press release 2019/06/04
Medivir to present at the 2019 BIO International Convention

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the 2019 BIO International Convention in...

Read more
Press release 2019/06/03
New data from the phase I study of birinapant in combination with Keytruda® presented at ASCO

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in...

Read more
Press release 2019/05/27
Medivir to present at the Redeye Pre-ASCO Seminar on May 28

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the Redeye Pre-ASCO Seminar in Stockholm....

Read more